Claims
- 1. A method for modulating immune cell adhesion comprising administering to a cell or animal in need thereof an effective amount of a substance that modulates an ephrin or an Eph receptor.
- 2. The method according to claim 1, wherein said immune cell is a T cell, a precursor T cell, or a thymocyte.
- 3. A method for modulating chemotaxis or cell migration, or both, comprising administering to a cell or animal in need thereof an effective amount of a substance that modulates an ephrin or an Eph receptor.
- 4. A method for modulating apoptosis comprising administering to a cell or animal in need thereof an effective amount of a substance that modulates an ephrin or an Eph receptor.
- 5. The method of claim 4, wherein said apoptosis is apoptosis in thymocytes.
- 6. A method for treating cancer by modulating an adhesive, migratory or chemotactic property of a cancer cell, comprising administering to a cancer cell or to an animal having cancer an effective amount of a substance that modulates an ephrin or an Eph receptor.
- 7. A method for modulating an immune response comprising administering to a cell or animal in need thereof an effective amount of a substance that modulates an ephrin or an Eph receptor.
- 8. The method according to claim 6, wherein said immune response is a T cell response or thymocyte response.
- 9. A method for suppressing an immune response comprising administering to a cell or animal in need thereof an effective amount of a substance that modulates an ephrin or an Eph receptor.
- 10. The method according to claim 9, wherein said animal has an autoimmune disease, an allergy, a graft, or is a transplant recipient.
- 11. A method for inducing an immune response comprising administering to a cell or animal in need thereof an effective amount of a substance that modulates an ephrin or an Eph receptor.
- 12. The method according to claim 11, wherein said animal has cancer.
- 13. The method according to claim 1, wherein said ephrin is ephrin A1, ephrin A2, ephrin A3, ephrin A4, ephrin A5, ephrin A6, ephrin B1, ephrin B2 or ephrin B3.
- 14. The method according to claim 1, wherein said ephrin is of the ephrin-A subfamily.
- 15. The method according to claim 1, wherein said Eph receptor is EphA1, EphA2, EphA3, EphA4, EphA5, EphA6, EphA7, EphA8, EphB1, EphB2, EphB3, EphB4, EphB5 or EphB6.
- 16. The method according to claim 1, wherein said Eph receptor is of the Eph-A subfamily.
- 17. The method according to claim 1, wherein said substance is a substance selected from the group consisting of oligomeric or monomeric soluble ephrins, Eph receptors, antibodies capable of binding an ephrin or an Eph receptor, antisense molecules complementary to a nucleic acid molecule encoding an ephrin or an Eph receptor, peptide mimetics based on ephrins or Eph receptors, and non-proteinaceous compounds capable of binding to and activating or inhibiting an ephrin or an Eph receptor.
- 18. A pharmaceutical composition for modulating an immune response, modulating immune cell adhesion, modulating apoptosis, modulating cell proliferation, modulating chemotaxis or modulating immune cell migration, said composition comprising an effective amount of a substance that modulates ephrin or an Eph receptor.
- 19. The pharmaceutical composition according to claim 18, wherein said substance is a substance selected from the group consisting of oligomeric or monomeric soluble ephrins, Eph receptors, antibodies capable of binding an ephrin or an Eph receptor, antisense molecules complementary to a nucleic acid molecule encoding an ephrin or an Eph receptor, peptide mimetics based on ephrins or Eph receptors, and non-proteinaceous compounds capable of binding to and activating or inhibiting an ephrin or an Eph receptor.
- 20. A kit comprising a pharmaceutical composition according to claim 19, and instructions for use of said composition for modulating an immune response, modulating immune cell adhesion, modulating apoptosis, modulating cell proliferation, modulating chemotaxis or modulating immune cell migration.
- 21. A method for identifying a substance that modulates immune cell adhesion, comprising:
contacting an ephrin or an Eph receptor with a test substance; and determining whether said ephrin or Eph receptor is modulated in the presence of said test substance, a modulation of said ephrin or Eph receptor being an indication that said test substance is useful for modulating immune cell adhesion.
- 22. A method for identifying a substance that modulates chemotaxis or immune cell migration, comprising:
contacting an ephrin or an Eph receptor with a test substance; and determining whether said ephrin or Eph receptor is modulated in the presence of said test substance, a modulation of said ephrin or Eph receptor being an indication that said test substance is useful for modulating chemotaxis or immune cell migration.
- 23. A method for identifying a substance that modulates apoptosis, comprising:
contacting an ephrin or an Eph receptor with a test substance; and determining whether said ephrin or Eph receptor is modulated in the presence of said test substance, a modulation of said ephrin or Eph receptor being an indication that said test substance is useful for modulating apoptosis.
- 24. A method for identifying a substance that modulates an immune response, comprising:
contacting an ephrin or an Eph receptor with a test substance; and determining whether said ephrin or Eph receptor is modulated in the presence of said test substance, a modulation of said ephrin or Eph receptor being an indication that said test substance is useful for modulating an immune response.
- 25. A method for identifying a substance useful for treating cancer through modulation of an adhesive, migratory or chemotactic property of a cancer cell, comprising:
contacting an ephrin or an Eph receptor with a test substance; and determining whether said ephrin or Eph receptor is modulated in the presence of said test substance, a modulation of said ephrin or Eph receptor being an indication that said test substance is useful for treating cancer through modulation of an adhesive, migratory or chemotactic property of a cancer cell.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. provisional application Ser. No. 60/302,385, filed Jul. 3, 2001, which is incorporated by reference herein in its entirety.
PCT Information
Filing Document |
Filing Date |
Country |
Kind |
PCT/CA02/01012 |
7/3/2002 |
WO |
|
Provisional Applications (1)
|
Number |
Date |
Country |
|
60302385 |
Jul 2001 |
US |